Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
Topics & Concepts
IncretinMedicineGlucagon-like peptide 1 receptorLiraglutideInternal medicineEndocrinologyAgonistGlucagon-like peptide-1Type 2 diabetesReceptorDiabetes mellitusLiver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiet, Metabolism, and Disease